Now showing items 1-10 of 12
Pharmacy Benefit Management, Cost-Effectiveness Analysis and Drug Formulary Decisions
(Social Science & Medicine, 1997-08)
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting competition in the pharmaceutical ...
The Role of Cost-Effectiveness Analysis in Managed Care Decisions
R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
(International Journal of the Economics of Business, 1995-01-01)
This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase ...
The Costs and Returns to Pharmaceutical Research and Development
(Revista Internazionale di Scienze sociali (International Social Studies Review), 1992-09)
Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade
A New Look at the Returns and Risks to Pharmaceutical R&D
This study investigates the returns to R&D for 100 new drugs introduced into the United States during the decade of the 1970s. In contrast to prior studies, it incorporates several significant structural changes that have ...
Returns to R&D on new drug introductions in the 1980s.
(J Health Econ, 1994-12)
This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ...
Innovation and Structural Change in Pharmaceuticals and Biotechnology
(Industrial and Corporate Change, 1994)
Cost of innovation in the pharmaceutical industry.
(J Health Econ, 1991-07)
The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-tax average cost of new ...